Edition:
United States

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

5,800JPY
2:00am EDT
Change (% chg)

¥-74 (-1.26%)
Prev Close
¥5,874
Open
¥5,857
Day's High
¥5,908
Day's Low
¥5,789
Volume
781,200
Avg. Vol
1,242,126
52-wk High
¥6,304
52-wk Low
¥4,537

Latest Key Developments (Source: Significant Developments)

R&I affirms Shionogi & Co Ltd's rating at "A+" and announces stable outlook – R&I
Thursday, 19 Jan 2017 01:00am EST 

Shionogi & Co Ltd <4507.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" – R&I .Rating outlook stable– R&I.  Full Article

Shionogi & retires 22 mln treasury shares on Jan. 10
Tuesday, 10 Jan 2017 01:09am EST 

Shionogi & Co Ltd <4507.T>: Says the co retired 22 million shares(6.3 percent stake) of its common stock on Jan. 10 .Says the total shares outstanding is 329.1 million shares after the retirement.  Full Article

Shionogi to set up new units
Wednesday, 21 Dec 2016 12:18am EST 

Shionogi & Co Ltd <4507.T>: Says it will have new units on April 3, 2017 . Says new units will with name of Shionogi Administration Service Company Limited, Shionogi Career Development Center Company Limited, Shionogi Digital Science Company Limited, Shionogi Business Partner Company Limited, Shionogi Pharmacovigilance Center Company Limited, and Shionogi Marketing Solutions Company Limited .Says every new unit will be capitalized at 10 million yen respectively.  Full Article

Shionogi & Co says sales transfer of 21 product and tansfer of manufacturing and marketing approval
Monday, 1 Aug 2016 10:58pm EDT 

Shionogi & Co Ltd <4507.T>: Says it to transfer sale of 21 products on Dec. 1 and manufacturing and marketing approval after 2017 to Kyowa Pharmaceutical Industry Co., Ltd. .Says Kyowa Pharmaceutical Industry Co., Ltd. to pay 15.4 billion yen to the co on Dec. 1 for the sales transfer of 21 products.  Full Article

Lupin buys Japan's Shionogi's product portfolio<4507.T>
Monday, 1 Aug 2016 10:53pm EDT 

Lupin Ltd : Acquires branded product portfolio from Shionogi in Japan . To acquire 21 long-listed products from Shionogi & Co .  Full Article

Shionogi and Astellas Pharma looking to sell drug brands that have lost patent protection - Nikkei<4503.T><4507.T>
Monday, 4 Jul 2016 04:34pm EDT 

Nikkei: Shionogi and Astellas Pharma are looking to sell off drug brands that have lost patent protection - Nikkei . Shionogi could select buyers at the end of July; proceeds from the sales estimated at nearly 20 billion yen - Nikkei . Astellas could receive up to 50 billion yen by divesting several drugs - Nikkei .  Full Article

Shionogi & Co Ltd adjusts conversion price of 2019 due Euro Yen - denominated convertible bonds with warrants to 4,167.5 yen
Thursday, 23 Jun 2016 02:00am EDT 

Shionogi & Co Ltd <4507.T>:Says it adjusts conversion price of 2019 due Euro Yen - denominated convertible bonds with warrants to 4,167.5 yen from 4,177.6 yen, effective from April 1.  Full Article

ViiV Healthcare says FDA approves sNDA for dolutegravir
Friday, 10 Jun 2016 09:10am EDT 

Viiv Healthcare Ltd : ViiV Healthcare announces FDA approval to lower weight limit for dolutegravir in children and adolescents living with HIV . FDA has approved a supplemental new drug application for dolutegravir 10mg and 25mg oral tablets, reducing weight limit . FDA approved supplemental new drug application for dolutegravir oral tablets, reducing weight limit to at least 30kg Further company coverage: [IPO-VIHL.L] (Bengaluru Newsroom: +91 80 6749 1136).  Full Article

Shionogi & Co raises year-end dividend forecast to 34 yen per share for FY 2016
Monday, 25 Apr 2016 12:00am EDT 

Shionogi & Co Ltd:Raised year-end dividend forecast to 34 yen per share, to 32 yen per share, for the fiscal year ended March 2016.  Full Article

Shionogi enters into license and collaboration agreement with Roche
Sunday, 28 Feb 2016 11:00pm EST 

Shionogi & Co Ltd:Says it has entered into a license and collaboration agreement with F. Hoffmann-La Roche Ltd. for development and commercialization of its oral anti-influenza drug S-033188, discovered by Shionogi.  Full Article

More From Around the Web

Photo

Gilead challenges GSK with strong HIV drug data

LONDON Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.